Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.40 |
| ▸ | F10 | P00742 | 4/20 | 0.40 |
| ▸ | CALML3 | P27482 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SDHA | P31040 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890869 | 0.92 | MAOA (0.43) | MAOAF10CALML3MAOBLMNA | |
| SCHEMBL2896788 | 0.91 | F10 (0.40) | MAOAF10CALML3MAOBLMNA | |
| SCHEMBL2896279 | 0.90 | MAOA (0.51) | MAOAF10CALML3MAOBLMNA | |
| SCHEMBL2890769 | 0.89 | MAOA (0.44) | MAOAF10CALML3MAOBLMNA | |
| SCHEMBL5220387 | 0.86 | MAOA (0.45) | MAOACYP3A4CYP2C9 | |
| SCHEMBL2890867 | 0.84 | CALML3 (0.40) | MAOACALML3MAOBCYP2C19CYP3A4 | |
| SCHEMBL5223015 | 0.84 | CALML3 (0.42) | MAOAF10CALML3MAOBCYP2C19 | |
| SCHEMBL2890506 | 0.84 | CALML3 (0.42) | MAOAF10CALML3MAOBCYP2C19 | |
| SCHEMBL5223010 | 0.82 | KDM4E (0.39) | MAOACALML3MAOBCYP2C19CYP3A4 | |
| SCHEMBL2890683 | 0.82 | CALML3 (0.39) | MAOACALML3MAOBCYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | claimed |
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | disclosed |
| EP-1799677-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | Ranbaxy Laboratories Limited (IN) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038100-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | OXA1L, PDK4, MLYCD | MAOA 1717/4885F10 1709/4885CALML3 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.